VolitionRx Limited (NYSE MKT: VNRX) has presented data at the World Congress of GI Endoscopy (ENDO) 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.QTM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection. “This is a key clinical milestone in the launch of our Nu.QTM Triage product. This validation study, in a second population of 1,961 subjects, greatly assists us with sales and marketing efforts in the EU and Asia,” said Louise Day, Chief Marketing and Communications Officer at Volition.
The lead author of the study, Dr. Marielle Herzog, commented, “This data confirms the role that the Nu.QTM Triage test can play in accelerating the diagnosis of colorectal cancer.” The full data can be found at http://volitionrx.com/news/presentations
About Nu.QTM Colorectal Cancer Screening Triage Test
There is currently a significant strain on colonoscopy capacity which can lead to longer waiting times in European healthcare systems due to the expansion of colorectal cancer screening programs. Therefore, there is a pressing need to prioritise the colonoscopy referrals for those at high risk. Volitions aims to meet this need with its new Nu.QTM Colorectal Cancer Screening Triage Test. Having received a CE mark for the Nu.QTM Colorectal Cancer Screening Triage Test in December 2016, Volition plans to launch the test for the European Union screening population.
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid — an indication that disease is present. As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition’s research and development activities are currently centered in Belgium, with additional offices in London, New York, Austin, TX and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition’s website (http://www.volitionrx.com) or connect with us via: